Search | Pharmaceuticals

1 - 10 of about 140 Documents

Why we Partner

We want to continue developing innovative treatments as efficiently as possible so we value collaboration with likeminded partners who share our quest to provide new options for patients.

https://pharma.bayer.com/why-we-partner

High Blood Pressure

When the heart beats, it pumps blood into the arteries, building up pressure – systolic blood pressure – on the walls of the blood vessels.

https://pharma.bayer.com/high-blood-pressure

Chronic Kidney Disease

Chronic kidney disease (CKD) is one of the most frequent complications arising from diabetes and is an independent risk factor of cardiovascular disease.

https://pharma.bayer.com/chronic-kidney-disease

Stroke & Atrial Fibrillation

Stroke is the second most common cause of death worldwide, responsible for 6.7 million deaths each year. Of those who survive a stroke, 5 million are left disabled every year.

https://pharma.bayer.com/stroke-atrial-fibrillation

Pulmonary Hypertension

Pulmonary hypertension is a disorder in which the blood vessels in the lungs become more and more narrow. As a result, less blood reaches the air sacs (alveoli) in the lungs, hampering oxygen uptake.

https://pharma.bayer.com/pulmonary-hypertension

Transparency

For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first.

https://pharma.bayer.com/transparency

Treating Lung Cancer With Precision Oncology - Kerstin’s Story

I was diagnosed with lung cancer in March 2017. I had pains on my right and left side and decided to go and see a doctor.

https://pharma.bayer.com/treating-lung-cancer-precision-oncology-kerstins-story

Oncology Treatment’s Next Frontier: Precision Medicine

At the recent ASCO congress, the annual meeting of the American Society of Clinical Oncology, I had the opportunity to connect in various meetings and discussions with the Oncology Community.

https://pharma.bayer.com/reaching-next-frontier-oncology-treatment-precision-medicine

Exclusive Treatment Approved for Rare TRK Fusion Cancers

Approval of first tumor-agnostic therapy in Europe marks meaningful advancement in cancer care.

https://pharma.bayer.com/approval-first-tumor-agnostic-therapy-europe

Survival Signaling

The 'survival signaling' research field is concerned with blocking the survival signals of the cancer cells.

https://pharma.bayer.com/survival-signaling